munotes®

MSc Biotechnology SEM III BIOTECHNOLOGY BIOLOGICS AND REGULATORY AFFAIRS Question Paper - Mumbai University | munotes

MSC. SEM III JAN.23 CHOICE BASED BIOTECHNOLOGY BIOLOGICS AND REGULATORY AFFAIRS (PD 3 JAN.23).pdf
SEM III · 106 KB · 1 May 2025

Loading PDF...

Questions asked in this paper

  • 3) Figures to the right indicate full marks
  1. Q4 All questions carry equal marks Answer the following (Any Two): 12
    • a) | What do you mean by Small molecules as biologics and biosimilars? Discuss any 2 distinguishing points between large molecules and small molecules
    • b) | What do you mean by Biogenerics? Give any 2 examples of USFDA approved biogenerics and state its use in therapeutics
    • c) Discuss Enzymes as Biologics. Give 2 examples of the USFDA approved Enzymes used in therapeutics and diagnostics
    • d) on the role DCGI in the regulatory process of Biosimilars in India
  2. Q2 Attempt the following (Any two): 12 marks
    • a) cell line? Explain the stability of the cell lines
    • b) What is scale up manufacturing? Explain with some tips to help scale up
    • c) Explain the steps in the production of monoclonal antibodies
    • d) the concept of biosimilars with examples Give an account of the following (Any two): 12
    • a) | How Mass spectra and Fluorescence spectra can be helpful in biosimilar
    • b) Give details of any 3 proteolytic enzymes which are used while characterization of
    • c) Elaborate on Isoelectric Focusing (IEF) method used for analysis of post translation modifications in biosimilar products
    • d) How size and purity of biosimilar product can be analysed by PAGE? Answer the following (Any two): 12
    • a) Explain in detail — Regulation of biosimilars
    • b) Discuss India-biosimilar regulatory requirements in detail
    • c) in detail — Biological product
    • d) Elaborate on — Abbreviated licensure pathway
  3. Q5 Write short notes on (Any Three): 12 marks
    • a) Vaccines as Biologics
    • b) Manufacturing conditions
    • c) Virus filtration
    • d) blotting for biosimilar analysis
    • f) trials initiation and filling of biosimilar application

Read from the scan above, so a character or two may differ. The scan is the original.

Report or request

Something wrong on this page? Report it and we will check it against the scan.

Quick Help

No. The full paper opens straight away, with no login and nothing to pay.

Something wrong with this paper? Report it.

Done!
Done!